The variety of individuals residing with neurological issues, similar to Alzheimer’s illness, epilepsy, a number of sclerosis and Parkinson’s illness, has elevated because the inhabitants has aged. On the identical time, technological develops, similar to mind mapping, have improved.
Non-public fairness companies are investing in a variety of firms concerned in therapies, together with drug improvement, infusion companies and medical gadgets. Right here, PE Hub highlights 5 latest offers, beginning with the most recent announcement.
1. InTandem Capital-backed Vivo Infusion snaps up Neurology Institute of San Antonio and Vista Infusions
Vivo Infusion, a portfolio firm of InTandem Capital Companions, introduced this month its acquisition of the Neurology Institute of San Antonio and Vista Infusions.
“NISA and Vista proceed Vivo’s emphasis as an infusion supplier of alternative for neurological and autoimmune illnesses,” stated Steve Rodgers, chief govt of Vivo Infusion, within the deal announcement. “We consider that by partnering with main doctor practices… we will advance the standard of take care of sufferers whereas enhancing worth.”
InTandem mergered MPP Infusion Facilities and ID Consultants to kind Vivo Infusion in 2022.
2. Archimed sells majority stake of Ad-Tech
In November, Archimed introduced that it offered a 71.4 p.c stake in Ad-Tech to Nihon Kohden, incomes a 5x return on its funding within the firm in 2020.
Working out of Oak Tree, Wisconsin, Ad-Tech manufactures minimally invasive gadgets referred to as intracranial neuro electrodes, that are used for mapping sufferers’ brains to diagnose and deal with neurological issues similar to epilepsy.
Nihon is predicated in Tokyo and has entered a three way partnership with Archimed as a part of the deal to pursue Ad-Tech’s progress in North America, Europe and Asia, in response to a launch.
Archimed, a healthcare-focused PE agency primarily based in Lyon, France, has retained a 28.6 p.c stake in Ad-Tech by means of the Med II fund below the three way partnership.
3. EQT Life Sciences invests in biotech firm Asceneuron
Final July, EQT Life Sciences introduced its funding in Asceneuron, a scientific stage biotech firm creating small molecules that concentrate on tau protein aggregation, a root explanation for neurodegenerative illnesses.
Asceneuron is predicated in Lausanne, Switzerland, the place it’s creating clinical-stage small molecule O-GlcNAcase enzyme inhibitors ASN90 for the remedy of progressive supranuclear palsy and ASN51 for Alzheimer’s illness. It is also planning to advance its pre-clinical improvement pipeline in Parkinson’s illness, amyotrophic lateral sclerosis and different neurodegenerative indications.
EQT, headquartered in Stockholm, invested within the firm by way of LSP Dementia Fund.
4. Companions Group goes for majority stake in FairJourney Biologics
Additionally in July, Companions Group introduced an settlement to accumulate a majority stake in FairJourney Biologics, an antibody discovery contract analysis group, from GHO Capital Companions for round €900 million broadly.
FairJourney is headquartered in Porto, Portugal, and gives companies for the invention, engineering, manufacturing and characterization of antibodies and helps within the improvement of 14 therapies to deal with unmet affected person wants throughout oncology, immunology and heart problems.
Pascal Noth, head of personal fairness well being and life, Europe at Companions, informed PE Hub in an interview on the deal that antibodies additionally maintain important potential for treating and enhancing affected person outcomes in neurology in addition to for autoimmune and a spread of different illnesses. This potential, together with the corporate’s 35-50 p.c annual historic progress price, is among the many causes that attracted Companions Group to spend money on FairJourney.
“We’ll proceed to spend money on the corporate to maintain that progress up, supporting the launch of latest applied sciences organically. The [antibody] market itself is at the moment rising at 15-17 p.c and inside that FairJourney is clearly taking market share.”
Companions is predicated in Zug, Switzerland, and oversees over $150 billion in belongings below administration. Its non-public fairness well being and life vertical has remodeled 30 direct investments.
Based mostly in London, GHO invested in FairJourney in 2020.
5. Renovus-backed ToxStrategies picks up Clintrex Analysis Company
Scientific consulting agency ToxStrategies, which is backed by Renovus Capital Companions, introduced in June its acquisition of Clintrex Analysis Company.
Clintrex is predicated in Sarasota, Florida, and gives scientific, scientific trial, operational and regulatory help to pharmaceutical and biotech firms within the improvement of therapies for central nervous system illness, a time period used to explain a gaggle of neurological issues that have an effect on the mind and backbone.
Renovus invested in ToxStrategies in 2022.
